It's difficult to keep up with evidence-based practices in education, infectious diseases, and optimizing health. I help by disseminating knowledge and providing education.
🌐 FakhriRavari.com

πŸ“‰ Pharmacokinetics-Pharmacodynamics of Vancomycin Objective 8 | Vancomycin Toxicodynamics πŸ›‘οΈβš οΈ
5:57
πŸ“‰ Pharmacokinetics-Pharmacodynamics of Vancomycin Objective 8 | Vancomycin Toxicodynamics πŸ›‘οΈβš οΈ
πŸ“‰ Pharmacokinetics-Pharmacodynamics of Vancomycin Objective 7 | Quick Vancomycin AUC Approximation πŸ“
14:26
πŸ“‰ Pharmacokinetics-Pharmacodynamics of Vancomycin Objective 7 | Quick Vancomycin AUC Approximation πŸ“
πŸ“‰ Pharmacokinetics-Pharmacodynamics of Vancomycin Objective 6 | Dialysis Dosing Demystified πŸ•’πŸ’§
4:36
πŸ“‰ Pharmacokinetics-Pharmacodynamics of Vancomycin Objective 6 | Dialysis Dosing Demystified πŸ•’πŸ’§
πŸ“‰ Pharmacokinetics-Pharmacodynamics of Vancomycin Objective 5 | Precision Dosing (Trough-Guided) πŸŽ›οΈπŸ”
10:40
πŸ“‰ Pharmacokinetics-Pharmacodynamics of Vancomycin Objective 5 | Precision Dosing (Trough-Guided) πŸŽ›οΈπŸ”
πŸ“‰ Pharmacokinetics-Pharmacodynamics of Vancomycin Objective 4 | Vancomycin Dosing Based on Pop PK πŸ“ŠπŸ§ 
7:55
πŸ“‰ Pharmacokinetics-Pharmacodynamics of Vancomycin Objective 4 | Vancomycin Dosing Based on Pop PK πŸ“ŠπŸ§ 
πŸ“‰ Pharmacokinetics-Pharmacodynamics of Vancomycin Objective 3 | Empiric Maintenance Dosing πŸ“‹βœ…
6:05
πŸ“‰ Pharmacokinetics-Pharmacodynamics of Vancomycin Objective 3 | Empiric Maintenance Dosing πŸ“‹βœ…
πŸ“‰ Pharmacokinetics-Pharmacodynamics of Vancomycin Objective 2 | Loading Dose for MRSA in the ICU πŸ₯πŸ’₯
8:32
πŸ“‰ Pharmacokinetics-Pharmacodynamics of Vancomycin Objective 2 | Loading Dose for MRSA in the ICU πŸ₯πŸ’₯
πŸ“‰ Pharmacokinetics-Pharmacodynamics of Vancomycin Objective 1 | PK/PD You’ll Actually Use πŸ’ŠπŸ”¬
10:06
πŸ“‰ Pharmacokinetics-Pharmacodynamics of Vancomycin Objective 1 | PK/PD You’ll Actually Use πŸ’ŠπŸ”¬
🦴 Bone and Joint Infections Objective 5 | Monitoring Antimicrobials in Bone & Joint Infections πŸ“‹βœ…
5:57
🦴 Bone and Joint Infections Objective 5 | Monitoring Antimicrobials in Bone & Joint Infections πŸ“‹βœ…
🦴 Bone and Joint Infections Objective 3 | Evidence-Based Therapy for Bone & Joint Infections πŸ§ πŸ’Š
18:17
🦴 Bone and Joint Infections Objective 3 | Evidence-Based Therapy for Bone & Joint Infections πŸ§ πŸ’Š
🦴 Bone and Joint Infections Objective 4 | No-Go List (Poor Bone Penetration) 🧱🚫
5:43
🦴 Bone and Joint Infections Objective 4 | No-Go List (Poor Bone Penetration) 🧱🚫
🦴 Bone and Joint Infections Objective 1 | Bone vs Joint? Osteomyelitis, Septic Arthritis, & More ⚑🦿
10:43
🦴 Bone and Joint Infections Objective 1 | Bone vs Joint? Osteomyelitis, Septic Arthritis, & More ⚑🦿
🦴 Bone and Joint Infections Objective 2 | Usual Suspects: VO & PJI Pathogens You Must Know 🦠
1:50
🦴 Bone and Joint Infections Objective 2 | Usual Suspects: VO & PJI Pathogens You Must Know 🦠
πŸ’Š Hepatitis C Virus (HCV) Objective 6 | Live Well: Alcohol, Vaccines, & Harm Reduction πŸ›‘οΈπŸŒΏ
4:20
πŸ’Š Hepatitis C Virus (HCV) Objective 6 | Live Well: Alcohol, Vaccines, & Harm Reduction πŸ›‘οΈπŸŒΏ
πŸ’Š Hepatitis C Virus (HCV) Objective 5 | Side Effects, What to Expect & How to Stay On-Therapy πŸ—£οΈπŸ’¬
2:30
πŸ’Š Hepatitis C Virus (HCV) Objective 5 | Side Effects, What to Expect & How to Stay On-Therapy πŸ—£οΈπŸ’¬
πŸ’Š Hepatitis C Virus (HCV) Objective 4 | Labs, Milestones & SVR (Practical Playbook) πŸ“‹βœ…
8:51
πŸ’Š Hepatitis C Virus (HCV) Objective 4 | Labs, Milestones & SVR (Practical Playbook) πŸ“‹βœ…
πŸ’Š Hepatitis C Virus (HCV) Objective 3 | DDIs Made Easy: Acid Reducers, Amiodarone, Statins, & More 🚦
6:50
πŸ’Š Hepatitis C Virus (HCV) Objective 3 | DDIs Made Easy: Acid Reducers, Amiodarone, Statins, & More 🚦
πŸ’Š Hepatitis C Virus (HCV) Objective 2 | First-Line Therapy (AASLD-IDSA) 🧭🧠
16:19
πŸ’Š Hepatitis C Virus (HCV) Objective 2 | First-Line Therapy (AASLD-IDSA) 🧭🧠
πŸ’Š Hepatitis C Virus (HCV) Objective 1 | HCV Under the Microscope 🧬πŸ§ͺ
27:24
πŸ’Š Hepatitis C Virus (HCV) Objective 1 | HCV Under the Microscope 🧬πŸ§ͺ
🦢 Skin and Soft Tissue Infections Objective 4 | Nec-Fas Masterclass 🚨🩸
10:03
🦢 Skin and Soft Tissue Infections Objective 4 | Nec-Fas Masterclass 🚨🩸
🦢 Skin and Soft Tissue Infections Objective 3 | Therapy for Cellulitis, Abscess & Impetigo πŸ’Šβœ…
26:33
🦢 Skin and Soft Tissue Infections Objective 3 | Therapy for Cellulitis, Abscess & Impetigo πŸ’Šβœ…
🦢 Skin and Soft Tissue Infections Objective 2 | Cellulitis, Abscess, Erysipelas… or Nec Fasc? πŸ§ͺ🦠
14:46
🦢 Skin and Soft Tissue Infections Objective 2 | Cellulitis, Abscess, Erysipelas… or Nec Fasc? πŸ§ͺ🦠
🦢 Skin and Soft Tissue Infections Objective 1 | Allergy Cross-Fire: PCNs v Cephs v Penems v Mono βš οΈπŸ’‰
17:50
🦢 Skin and Soft Tissue Infections Objective 1 | Allergy Cross-Fire: PCNs v Cephs v Penems v Mono βš οΈπŸ’‰
πŸ’© Clostridioides difficile Infection (C diff) Objective 4 | Treating C diff Right πŸ’₯πŸ“‹
12:51
πŸ’© Clostridioides difficile Infection (C diff) Objective 4 | Treating C diff Right πŸ’₯πŸ“‹
πŸ’© Clostridioides difficile Infection (C diff) Objective 3 | Is It Really C diff? πŸ§ͺ🧬
8:55
πŸ’© Clostridioides difficile Infection (C diff) Objective 3 | Is It Really C diff? πŸ§ͺ🧬
πŸ’© Clostridioides difficile Infection (C diff) Objective 2 | Risks for First-Time & Recurrent CDI ⚠️πŸ”₯
13:57
πŸ’© Clostridioides difficile Infection (C diff) Objective 2 | Risks for First-Time & Recurrent CDI ⚠️πŸ”₯
πŸ’© Clostridioides difficile Infection (C diff) Objective 1 | Inside the Gut πŸ”¬πŸ§ 
16:24
πŸ’© Clostridioides difficile Infection (C diff) Objective 1 | Inside the Gut πŸ”¬πŸ§ 
πŸ₯ Nosocomial Pneumonia and Pneumococcal Vaccines | Empiricβ†’Targeted Therapy, IVβ†’PO, & Prevention πŸ’‰πŸ’Š
35:14
πŸ₯ Nosocomial Pneumonia and Pneumococcal Vaccines | Empiricβ†’Targeted Therapy, IVβ†’PO, & Prevention πŸ’‰πŸ’Š
πŸ’‰ 2025-2026 Influenza Vaccination Recommendations (ACIP)
17:23
πŸ’‰ 2025-2026 Influenza Vaccination Recommendations (ACIP)
😷 Community-Acquired Pneumonia | PK/PD, Diagnosis, Risk Scores, Empiric Therapy & Duration πŸ’Š
1:18:11
😷 Community-Acquired Pneumonia | PK/PD, Diagnosis, Risk Scores, Empiric Therapy & Duration πŸ’Š